Literature DB >> 16941688

Hepatitis C virus entry: molecular biology and clinical implications.

Heidi Barth1, T Jake Liang, Thomas F Baumert.   

Abstract

With an estimated 170 million infected individuals, hepatitis C virus (HCV) has a major impact on public health. A vaccine protecting against HCV infection is not available, and current antiviral therapies are characterized by limited efficacy, high costs, and substantial side effects. Binding of the virus to the cell surface followed by viral entry is the first step in a cascade of interactions between virus and the target cell that is required for the initiation of infection. Because this step represents a critical determinant of tissue tropism and pathogenesis, it is a major target for host cell responses such as antibody-mediated virus-neutralization-and a promising target for new antiviral therapy. The recent development of novel tissue culture model systems for the study of the first steps of HCV infection has allowed rapid progress in the understanding of the molecular mechanisms of HCV binding and entry. This review summarizes the impact of recently identified viral and host cell factors for HCV attachment and entry. Clinical implications of this important process for the pathogenesis of HCV infection and novel therapeutic interventions are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941688     DOI: 10.1002/hep.21321

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus.

Authors:  Fumi Kobayashi; Shuhei Yamada; Shuhei Taguwa; Chikako Kataoka; Satomi Naito; Yoshiki Hama; Hideki Tani; Yoshiharu Matsuura; Kazuyuki Sugahara
Journal:  Glycoconj J       Date:  2012-06-03       Impact factor: 2.916

2.  HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity.

Authors:  Nagako Akeno; Jason T Blackard; Yaron Tomer
Journal:  J Autoimmun       Date:  2008-09-16       Impact factor: 7.094

Review 3.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

4.  Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry.

Authors:  Ignacio Benedicto; Francisca Molina-Jiménez; Ricardo Moreno-Otero; Manuel López-Cabrera; Pedro L Majano
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

5.  High level of serum cholesteryl ester transfer protein in active hepatitis C virus infection.

Authors:  Kenichi Satoh; Tomohisa Nagano; Nobuyoshi Seki; Yoichi Tomita; Yuta Aida; Tomonori Sugita; Munenori Itagaki; Satoshi Sutoh; Hiroshi Abe; Yoshio Aizawa
Journal:  World J Hepatol       Date:  2016-02-18

Review 6.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

7.  Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts.

Authors:  Lisa Cukierman; Laurent Meertens; Claire Bertaux; Francis Kajumo; Tatjana Dragic
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 8.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 9.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).

Authors:  David H Dreyfus; S Mark Tompkins; Ramsay Fuleihan; Lucy Y Ghoda
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.